SG11202103118PA - Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof - Google Patents

Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof

Info

Publication number
SG11202103118PA
SG11202103118PA SG11202103118PA SG11202103118PA SG11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA
Authority
SG
Singapore
Prior art keywords
preparation
crystal form
method therefor
quinazoline compound
morpholino quinazoline
Prior art date
Application number
SG11202103118PA
Inventor
Zusheng Xu
Yangtong Lou
Original Assignee
Shanghai Yingli Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yingli Pharmaceutical Co Ltd filed Critical Shanghai Yingli Pharmaceutical Co Ltd
Publication of SG11202103118PA publication Critical patent/SG11202103118PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202103118PA 2018-09-27 2019-09-12 Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof SG11202103118PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811131702 2018-09-27
PCT/CN2019/105688 WO2020063368A1 (en) 2018-09-27 2019-09-12 Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof

Publications (1)

Publication Number Publication Date
SG11202103118PA true SG11202103118PA (en) 2021-04-29

Family

ID=69953307

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103118PA SG11202103118PA (en) 2018-09-27 2019-09-12 Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof

Country Status (13)

Country Link
US (1) US11168072B2 (en)
EP (1) EP3858830B1 (en)
JP (1) JP7071588B2 (en)
KR (1) KR20210069664A (en)
CN (1) CN110950844B (en)
AU (1) AU2019345706B2 (en)
BR (1) BR112021006026A2 (en)
CA (1) CA3114260A1 (en)
EA (1) EA202190880A1 (en)
MX (1) MX2021003576A (en)
SG (1) SG11202103118PA (en)
TW (1) TWI820223B (en)
WO (1) WO2020063368A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190880A1 (en) 2018-09-27 2021-06-28 Шанхай Инли Фармасьютикал Ко., Лтд CRYSTALLINE FORM OF MORPHOLINOQUINAZOLINE COMPOUND, METHOD OF ITS PREPARATION AND ITS APPLICATION
WO2022199375A1 (en) * 2021-03-26 2022-09-29 上海璎黎药业有限公司 Pharmaceutical composition of quinazoline compound and preparation method therefor
CN115252620A (en) * 2021-04-30 2022-11-01 上海璎黎药业有限公司 Application of quinazoline compound and pharmaceutical composition
TW202315615A (en) * 2021-09-01 2023-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Use of pi3k inhibitor and btk inhibitor in preparing medicine for treating lymphoma
WO2024041519A1 (en) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 Morpholinyl quinazoline compound, and pharmaceutical composition and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2209786T3 (en) 2007-10-05 2013-06-03 Verastem Inc PYRIMIDINE-SUBSTITUTED PURINDER DERIVATIVES
KR20110042153A (en) 2008-05-30 2011-04-25 제넨테크, 인크. Purine pi3k inhibitor compounds and methods of use
AU2014336775B2 (en) 2013-10-16 2018-04-05 Shanghai Yingli Pharmaceutical Co., Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
BR112016029846A2 (en) * 2014-06-24 2017-08-22 Gilead Sciences Inc compound, pharmaceutical composition, methods for the method of treating a human, for inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide and over inhibiting or destructive immune reactions or cancer cell growth or proliferation, kit, and, use of a compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof?
CN108430990B (en) * 2015-12-25 2020-08-25 山东轩竹医药科技有限公司 Crystal of quinazoline derivative and method for producing same
EA202190880A1 (en) 2018-09-27 2021-06-28 Шанхай Инли Фармасьютикал Ко., Лтд CRYSTALLINE FORM OF MORPHOLINOQUINAZOLINE COMPOUND, METHOD OF ITS PREPARATION AND ITS APPLICATION

Also Published As

Publication number Publication date
CN110950844B (en) 2024-01-30
AU2019345706A1 (en) 2021-05-27
TWI820223B (en) 2023-11-01
TW202024066A (en) 2020-07-01
EP3858830A4 (en) 2021-09-15
EP3858830A1 (en) 2021-08-04
MX2021003576A (en) 2021-05-28
EP3858830B1 (en) 2022-11-16
CN110950844A (en) 2020-04-03
US11168072B2 (en) 2021-11-09
KR20210069664A (en) 2021-06-11
CA3114260A1 (en) 2020-04-02
US20210317104A1 (en) 2021-10-14
WO2020063368A1 (en) 2020-04-02
EA202190880A1 (en) 2021-06-28
BR112021006026A2 (en) 2021-06-29
JP2021528487A (en) 2021-10-21
AU2019345706B2 (en) 2024-02-22
JP7071588B2 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
SG11202103118PA (en) Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
ZA202001447B (en) M-diamide compound and preparation method therefor and use thereof
EP3502113A4 (en) Pharmaceutically acceptable salt of egfr inhibitor, crystal form thereof, preparation method therefor and application thereof
EP3246328A4 (en) Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof
EP3470400A4 (en) Crystal form of ozanimod, crystal form of hydrochloride thereof, and preparation method therefor
EP3269719A4 (en) Crystal form of jak inhibitor and preparation method thereof
EP3508481A4 (en) Crystal form of ozanimod hydrochloride, and preparation method therefor
EP3647312A4 (en) Crystal form of deuterated azd9291, preparation method therefor, and use thereof
EP3269711A4 (en) Stable apremilast crystal form ii free of solvates, and preparation method therefor
EP3812378A4 (en) Crystal form of arn-509, preparation method therefor and use thereof
HK1256860A1 (en) Crystals of quinazoline derivative and preparation method therefor
EP3502100A4 (en) Crystal forms of ozanimod and preparation method therefor
EP3495352A4 (en) Crystal form of androgen receptor antagonist medication, preparation method therefor, and use
EP3312151A4 (en) Oxidation-induced self-healing ceramic composition containing healing activator, method for producing same, use of same, and method for enhancing functionality of oxidation-induced self-healing ceramic composition
EP3941459A4 (en) Quinoline and quinazoline compounds and methods of use thereof
EP3530650A4 (en) Crystalline form of (r)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof
EP3369733A4 (en) Crystal form of 4h-pyrazolo[1,5- ]benzoimidazole compound, preparation method therefor and intermediate thereof
EP3805229C0 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
EP3330267A4 (en) Salt of quinazoline derivative or crystal thereof, and method for producing salt of quinazoline derivative or crystal thereof
IL263868A (en) Crystal form of 9-aminomethyl substituted tetracycline compounds and preparation method therefor
HK1252375A1 (en) Crystals of quinazoline derivative and preparation method therefor
EP3736273A4 (en) Novel crystal form of acalabrutinib and preparation method and use thereof
HK1258757A1 (en) Salt type and crystal type of 4h-pyrazolo[1, 5-alpha]benzimidazole compound and preparation method and intermediate thereof
IL310703A (en) Crystal form of lanifibranor, preparation method therefor, and use thereof
ZA202107810B (en) Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof